Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Receipts on Account of Share to be Allotted [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Equity Attributable to Orgenesis Inc. [Member]
Non-Controlling Interest [Member]
Total
Beginning Balance at Nov. 30, 2016 $ 1 $ 45,454   $ (1,205) $ (31,753) $ 12,497   $ 12,497
Beginning Balance (Shares) at Nov. 30, 2016 9,508,068              
Stock-based compensation to employees and directors   1,156       1,156   1,156
Stock-based compensation to service providers   1,824       1,824   1,824
Stock-based compensation to service providers (Shares) 79,167              
Issuance of warrants and beneficial conversion feature of convertible loans   2,550       2,550   2,550
Issuance of shares and receipts on account of shares and warrants to be allotted   3,383 $ 852     4,235   4,235
Issuance of shares and receipts on account of shares and warrants to be allotted (Shares) 244,743              
Comprehensive income (loss) for the period       2,419 (12,557) (10,138)   (10,138)
Ending Balance at Aug. 31, 2017 $ 1 54,367 852 1,214 (44,310) 12,124   12,124
Ending Balance (Shares) at Aug. 31, 2017 9,831,978              
Beginning Balance at Nov. 30, 2017 $ 1 55,334 1,483 1,425 (44,120) 14,123   14,123
Beginning Balance (Shares) at Nov. 30, 2017 9,872,659              
Stock-based compensation to employees and directors   1,416       1,416   1,416
Stock-based compensation to service providers   1,568       1,568   1,568
Stock-based compensation to service providers (Shares) 195,000              
Issuance of shares from investments and conversion of convertible loans (Shares) 1,341,134              
Issuance of warrants and beneficial conversion feature of convertible loans   7,330       7,330   7,330
Issuance of shares and receipts on account of shares to be allotted related to acquisition of Atvio and CureCell   600 1,853     2,453 $ 300 2,753
Issuance of shares and receipts on account of shares to be allotted related to acquisition of Atvio and CureCell (Shares) 83,965              
Issuance of shares and receipts on account of shares and warrants to be allotted   13,466 2,154     15,620   15,620
Issuance of shares and receipts on account of shares and warrants to be allotted (Shares) 1,990,858              
Beneficial conversion feature of convertible loans and Warrants issued   323       323   323
Issuance of Shares due to exercise of warrants   852       852   852
Issuance of Shares due to exercise of warrants (Shares) 136,646              
Comprehensive income (loss) for the period       (765) (13,295) (14,060) 39 (14,021)
Ending Balance at Aug. 31, 2018 $ 1 $ 80,889 $ 5,490 $ 660 $ (57,415) $ 29,625 $ 339 $ 29,964
Ending Balance (Shares) at Aug. 31, 2018 13,620,262